Holger Engel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Holger Engel has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Christoph Heitmann
Berufsgenossenschaftliche Unfallklinik Ludwigshafen, Plastische und Handchirurgie an der Universität Heidelberg
1 shared publication Günter Germann
1 shared publication- Günter Germann
Ethianum for Clinic Plastic, Hand and Reconstructive Surgery, University of Heidelberg, Heidelberg, Germany
1 shared publication Markus V. Küntscher
1 shared publicationMichael Pelzer
1 shared publicationMichael Sauerbier
1 shared publication
Latest Publications
- 1 April 2007
- Published by Wolters Kluwer Health in Annals of Plastic Surgery
- Vol. 58 (4) , 456-460
Dose-Dependent Effects of a Nitric Oxide Donor in a Rat Flap Model
Previous studies have proven the effectiveness of nitric oxide (NO) donors to enhance flap survival in experimental models. The purpose of this study was to determine the ideal dose of the NO donor spermine/nitric oxide complex (Sper/NO) with respect to flap survival and hemodynamic side effects. Additionally, the influence of the type of application (systemically versus intra-arterial into the flap artery) was observed.Seventy-two male Wistar rats were divided into 9 experimental groups. An extended epigastric adipocutaneous flap (6 x 10 cm) based on the left superficial epigastric artery and vein was raised in each animal. The average percentage of flap necrosis was 69.8% in the control group with ischemia and 29.8% in the non ischemic controls. The average necrosis areas in the 3 groups after preischemic intravenous (i.v.) application of Sper/NO (250, 500, and 750 nmol/kg body weight) were 63.5%, 33.8%, and 38.4%, respectively. The application of similar doses into the flap artery resulted in 63.5%, 72.3%, and 64.3% flap necrosis; 52.7% average flap loss was observed in an additional group receiving Sper/NO adjusted to flap weight (500 nmol/kg flap weight). Only the intravenous application of 500 and 750 nmol/kg resulted in a significant reduction of flap necrosis compared with the ischemic controls (P < 0.01). The drop in mean arterial pressure was less after i.v. application of 500 nmol/kg Sper/NO compared with 750 nmol. Our data show that the preischemic intravenous application of 500 nmol/kg Sper/NO achieved the best results with acceptable side effects. A dose of 250 nmol/kg i.v., as well as the application of Sper/NO into the flap artery, was demonstrated to be ineffective.
- 1 April 2007
- Published by Wolters Kluwer Health in Annals of Plastic Surgery
- Vol. 58 (4) , 456-460
Dose-Dependent Effects of a Nitric Oxide Donor in a Rat Flap Model
Previous studies have proven the effectiveness of nitric oxide (NO) donors to enhance flap survival in experimental models. The purpose of this study was to determine the ideal dose of the NO donor spermine/nitric oxide complex (Sper/NO) with respect to flap survival and hemodynamic side effects. Additionally, the influence of the type of application (systemically versus intra-arterial into the flap artery) was observed.Seventy-two male Wistar rats were divided into 9 experimental groups. An extended epigastric adipocutaneous flap (6 x 10 cm) based on the left superficial epigastric artery and vein was raised in each animal. The average percentage of flap necrosis was 69.8% in the control group with ischemia and 29.8% in the non ischemic controls. The average necrosis areas in the 3 groups after preischemic intravenous (i.v.) application of Sper/NO (250, 500, and 750 nmol/kg body weight) were 63.5%, 33.8%, and 38.4%, respectively. The application of similar doses into the flap artery resulted in 63.5%, 72.3%, and 64.3% flap necrosis; 52.7% average flap loss was observed in an additional group receiving Sper/NO adjusted to flap weight (500 nmol/kg flap weight). Only the intravenous application of 500 and 750 nmol/kg resulted in a significant reduction of flap necrosis compared with the ischemic controls (P < 0.01). The drop in mean arterial pressure was less after i.v. application of 500 nmol/kg Sper/NO compared with 750 nmol. Our data show that the preischemic intravenous application of 500 nmol/kg Sper/NO achieved the best results with acceptable side effects. A dose of 250 nmol/kg i.v., as well as the application of Sper/NO into the flap artery, was demonstrated to be ineffective.
- 1 October 2006
- Published by Georg Thieme Verlag KG in Journal of Reconstructive Microsurgery
- Vol. 22 (08) , A022
Management of ASA III and IV Patients for Chest-Wall Reconstruction
The authors reported on their treatment of a small group of patients with recurrent cancer/osteoradionecrosis of the chest wall or sternum osteomyelitis. The patients qualified for this group by being ASA III or IV and having had multiple previous operations (El Oakley III to V). All patients needed a free flap as the alternative options of the reconstructive ladder were no longer available. Between March 1997 and March 2004, 14 patients were operated on (cancer/osteoradionecrosis − 7; sternum osteomyelitis − 7). There were 11 females and 3 males with an average age of 61.9 years (range: 54-82 years). All patients received a free tensor fasciae latae (TFL) fflap. No flap was lost. The anastomoses had to be revised in three cases with subsequent uneventful course. The operating time was 6.1 hr on average (range: 4.7 to 8.4 hr). The procedure was always performed by two teams and no repositioning was necessary. The postoperative ventilation time was 180.7 hr on average (range: 9–338 hr). The mean hospital stay was 51 days (range: 13–135 days). Five patients died within 6 months postoperatively due to their underlying chronic illness (3 ×) or multiple organ failure (2 ×). The free TFL flap remains the flap of choice in these seriously ill patients with chest-wall reconstruction. It is reliable and easy to harvest without a noticeable donor-site morbidity. The semi-rigid layer of the fascia lata is an important component of the flap that provides additional structural support at the site of the chest-wall reconstruction. Within the latest five cases, the descending branch of the lateral circumflex femoral artery was included in the flap, and a combined TFL/ALT free flap was raised. This modification augments the blood flow to the former distal part of the TFL and helps overall flap survival. The authors also anastomose the flap to a loop that runs from the cephalic vein to the thoracoacromial artery. With this maneuver, the recipient vessels are readily available at the time of the anastomosis and positioning of the flap is much easier. Although five of 14 patients were lost within 6 months postoperatively, a persisting, fungating defect that is painful, infected, and bleeding is hardly an alternative for the patient's remaining life span.
- 1 October 2006
- Published by Georg Thieme Verlag KG in Journal of Reconstructive Microsurgery
- Vol. 22 (08) , A022
Management of ASA III and IV Patients for Chest-Wall Reconstruction
The authors reported on their treatment of a small group of patients with recurrent cancer/osteoradionecrosis of the chest wall or sternum osteomyelitis. The patients qualified for this group by being ASA III or IV and having had multiple previous operations (El Oakley III to V). All patients needed a free flap as the alternative options of the reconstructive ladder were no longer available. Between March 1997 and March 2004, 14 patients were operated on (cancer/osteoradionecrosis − 7; sternum osteomyelitis − 7). There were 11 females and 3 males with an average age of 61.9 years (range: 54-82 years). All patients received a free tensor fasciae latae (TFL) fflap. No flap was lost. The anastomoses had to be revised in three cases with subsequent uneventful course. The operating time was 6.1 hr on average (range: 4.7 to 8.4 hr). The procedure was always performed by two teams and no repositioning was necessary. The postoperative ventilation time was 180.7 hr on average (range: 9–338 hr). The mean hospital stay was 51 days (range: 13–135 days). Five patients died within 6 months postoperatively due to their underlying chronic illness (3 ×) or multiple organ failure (2 ×). The free TFL flap remains the flap of choice in these seriously ill patients with chest-wall reconstruction. It is reliable and easy to harvest without a noticeable donor-site morbidity. The semi-rigid layer of the fascia lata is an important component of the flap that provides additional structural support at the site of the chest-wall reconstruction. Within the latest five cases, the descending branch of the lateral circumflex femoral artery was included in the flap, and a combined TFL/ALT free flap was raised. This modification augments the blood flow to the former distal part of the TFL and helps overall flap survival. The authors also anastomose the flap to a loop that runs from the cephalic vein to the thoracoacromial artery. With this maneuver, the recipient vessels are readily available at the time of the anastomosis and positioning of the flap is much easier. Although five of 14 patients were lost within 6 months postoperatively, a persisting, fungating defect that is painful, infected, and bleeding is hardly an alternative for the patient's remaining life span.